AbbVie Bolsters Immunology Pipeline with $10.9 Billion Apogee Acquisition The acquisition would add a longer-acting alternative to Dupixent for inflammatory diseases. Credit: Apogee Therapeutics Subscribe now Already have an account? Sign in.
